Studies utilizing Aza combined with CpG1826 in a syngeneic lung cancer model showed that NK1.1 depletion greatly abrogated the efficacy of the combined treatment, as did CD8 depletion, illuminating the importance of both immune arms in tumor control (54). Here, CD8A is linked to lung cancer.